Hypervision Surgical has closed a £17 million Series A raise. The raise marks a meteoric rise for the King’s College London spin-out pioneering hyperspectral imaging for surgery.

The round, led by Heal Capital with participation from Angelini Ventures, IP Group, Daycrest, HERAN Partners, Redalpine, LifeX Ventures, and ZEISS Ventures, also includes strategic investment from the SINC Fund managed by SAGES Ingenuity, and Macmillan Cancer Support.

Surgeons have always made critical decisions based on what the human eye can see. Hypervision Surgical changes what’s visible.

The company’s Hyperspectral Intelligence platform moves beyond the visible spectrum by giving surgeons real-time, pixel-level insights into tissue physiology.

This new intelligence layer for the operating room is already cleared by the FDA and certified in the UK.